Acetylcysteine - Generic Drug Details

What are the generic sources for acetylcysteine and what is the scope of patent protection?

Acetylcysteine is the generic ingredient in eight branded drugs marketed by Cumberland Pharms, Eugia Pharma, Exela Pharma, Fresenius Kabi Usa, Glenmark Pharms Inc, Onesource Specialty, Regcon Holdings, Rising, Sagent Pharms Inc, Somerset Theraps Llc, Zydus Pharms, Alvogen, Am Regent, Conba Usa, Hospira, Roxane, Apothecon, DEY, Arbor Pharms Llc, Galephar, and Mead Johnson, and is included in thirty-two NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Acetylcysteine has nineteen patent family members in eleven countries.

There are three drug master file entries for acetylcysteine. Fourteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for acetylcysteine

International Patents:	19
US Patents:	6
Tradenames:	8
Applicants:	21
NDAs:	32
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	14
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	438
Patent Applications:	6,539
Drug Prices:	Drug price trends for acetylcysteine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for acetylcysteine
What excipients (inactive ingredients) are in acetylcysteine?	acetylcysteine excipients list
DailyMed Link:	acetylcysteine at DailyMed

See drug prices for acetylcysteine

Recent Clinical Trials for acetylcysteine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Arizona	PHASE2
Banner University Medical Center	PHASE2
Open Source Pharma Foundation	PHASE3

See all acetylcysteine clinical trials

Generic filers with tentative approvals for ACETYLCYSTEINE

Applicant	Application No.	Strength	Dosage Form
		6GM/30ML (200MG/ML)	INJECTABLE;INTRAVENOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for acetylcysteine

Drug Class	Antidote Antidote for Acetaminophen Overdose Mucolytic
Mechanism of Action	Reduction Activity
Physiological Effect	Decreased Respiratory Secretion Viscosity Increased Glutathione Concentration

Medical Subject Heading (MeSH) Categories for acetylcysteine

Antiviral Agents

Expectorants

Free Radical Scavengers

Anatomical Therapeutic Chemical (ATC) Classes for acetylcysteine

R05CB	Mucolytics
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

S01XA	Other ophthalmologicals
S01X	OTHER OPHTHALMOLOGICALS
S01	OPHTHALMOLOGICALS
S	Sensory organs

V03AB	Antidotes
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for ACETYLCYSTEINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ACETADOTE	Injection	acetylcysteine	200 mg/mL, 30 mL vials	021539	3	2012-04-04

US Patents and Regulatory Information for acetylcysteine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Exela Pharma	ACETYLCYSTEINE	acetylcysteine	SOLUTION;INHALATION, ORAL	205643-001	Nov 1, 2023		DISCN	No	No
Am Regent	ACETYLCYSTEINE	acetylcysteine	SOLUTION;INHALATION, ORAL	072489-001	Jul 28, 1995	AN	RX	No	Yes
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-001	Jan 29, 2016		DISCN	Yes	No
Apothecon	MUCOMYST	acetylcysteine	SOLUTION;INHALATION, ORAL	013601-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Glenmark Pharms Inc	ACETYLCYSTEINE	acetylcysteine	INJECTABLE;INTRAVENOUS	213693-001	Feb 3, 2022	AP	RX	No	No
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-002	Jan 29, 2016		DISCN	Yes	No

Expired US Patents for acetylcysteine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cumberland Pharms	ACETADOTE	acetylcysteine	INJECTABLE;INTRAVENOUS	021539-001	Jan 23, 2004
Cumberland Pharms	ACETADOTE	acetylcysteine	INJECTABLE;INTRAVENOUS	021539-001	Jan 23, 2004

International Patents for acetylcysteine

Country	Patent Number	Title	Estimated Expiration
China	103038356	Acetycysteine compositions and methods of use thereof
European Patent Office	1928449	COMPOSITION D'ACETYLCYSTEINE ET SES UTILISATIONS (ACETYLCYSTEINE COMPOSITION AND USES THEREFOR)
Australia	2006282030	Acetylcysteine composition and uses therefor
South Korea	101408336
Hong Kong	1123972	乙酰半胱氨酸組合物及其用途 (ACETYLCYSTEINE COMPOSITION AND USES THEREFOR)
World Intellectual Property Organization (WIPO)	2012012640

Acetylcysteine Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Acetylcysteine (NAC), a cysteine derivative, holds established therapeutic roles in mucolytic treatment and acetaminophen overdose reversal. Its market performance is influenced by established indications, emerging research, and generic competition.

What is Acetylcysteine and Its Primary Therapeutic Applications?

Acetylcysteine is an antioxidant and mucolytic agent. Its primary therapeutic applications are:

• Mucolytic Agent: NAC breaks disulfide bonds in mucoproteins, reducing mucus viscosity. It is administered via inhalation for respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and bronchitis [1].
• Acetaminophen Antidote: NAC is the standard treatment for acetaminophen (paracetamol) poisoning. It replenishes hepatic glutathione stores, which are depleted by the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) [2].

What is the Current Market Size and Projected Growth for Acetylcysteine?

The global acetylcysteine market was valued at approximately $800 million in 2023. The market is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2030. This growth is driven by an increasing prevalence of respiratory diseases, the rising incidence of acetaminophen overdose, and ongoing research into new therapeutic applications.

What are the Key Market Drivers for Acetylcysteine?

Key market drivers include:

• Rising Incidence of Respiratory Diseases: An aging global population and increased exposure to air pollution contribute to a higher incidence of COPD, asthma, and other chronic respiratory conditions. These conditions necessitate mucolytic treatments, boosting demand for acetylcysteine. The World Health Organization estimates that COPD affects 251 million people globally [3].
• Increasing Cases of Acetaminophen Overdose: Acetaminophen is widely available over-the-counter, leading to accidental or intentional overdoses. This drives consistent demand for NAC as the primary antidote. In the United States, acetaminophen overdose is a leading cause of acute liver failure [4].
• Expanding Research into New Indications: NAC is being investigated for potential benefits in psychiatric disorders (e.g., obsessive-compulsive disorder, addiction), neurological conditions, and as an adjuvant therapy in oncology. Positive outcomes in clinical trials could unlock new market segments.
• Generic Availability and Affordability: The widespread availability of generic acetylcysteine products makes it an accessible treatment option, particularly in emerging economies, thereby supporting volume growth.

What are the Primary Restraints and Challenges in the Acetylcysteine Market?

Primary market restraints and challenges include:

• Intense Generic Competition: The acetylcysteine market is highly fragmented with numerous generic manufacturers. This leads to significant price erosion and limits the pricing power of individual companies.
• Development of Alternative Therapies: For mucolytic indications, newer or more targeted therapies are emerging, potentially posing a competitive threat. Similarly, alternative antidotes for acetaminophen overdose could emerge, although NAC remains the gold standard.
• Regulatory Hurdles for New Indications: Obtaining regulatory approval for new therapeutic uses of acetylcysteine requires extensive clinical trials, which are time-consuming and costly.
• Limited Patent Expirations: Many core patents for acetylcysteine have long expired, with the focus now shifting to newer formulations or specific delivery methods.

What is the Competitive Landscape for Acetylcysteine Manufacturers?

The competitive landscape is characterized by a mix of large pharmaceutical companies and numerous smaller generic manufacturers. Key players in the acetylcysteine market include:

• Grup ACGS (Spain): A significant producer of acetylcysteine APIs and finished dosage forms.
• Sanofi S.A. (France): Markets acetylcysteine under brands like Mucomyst.
• Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.) (Canada): Has a presence in the mucolytic market with acetylcysteine-containing products.
• Chiesi Farmaceutici S.p.A. (Italy): Offers acetylcysteine formulations for respiratory indications.
• Exeltis (part of Cheplapharm Arzneimittel GmbH) (Germany): A producer of generic acetylcysteine.
• Teva Pharmaceutical Industries Ltd. (Israel): A major player in the global generics market, including acetylcysteine.

The market is competitive, with pricing and product availability being key differentiators among generic manufacturers.

What is the Regulatory Environment Affecting Acetylcysteine?

The regulatory environment for acetylcysteine is primarily governed by national drug regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others globally.

• Approval for Existing Indications: Manufacturers must adhere to Good Manufacturing Practices (GMP) and demonstrate bioequivalence for generic versions of established acetylcysteine products.
• New Indication Approval: For novel applications, extensive preclinical and clinical data supporting safety and efficacy are required, following rigorous review processes.
• Pharmacovigilance: Post-market surveillance for adverse events is mandatory.

What is the Impact of Intellectual Property on the Acetylcysteine Market?

The impact of intellectual property (IP) on the acetylcysteine market is limited for the original molecule due to patent expiries. However, IP strategies are now focused on:

• New Formulations: Patents may cover novel delivery systems (e.g., sustained-release formulations, specific inhalation devices) that improve patient compliance or efficacy.
• New Therapeutic Uses: Patents can be obtained for the use of acetylcysteine in treating specific diseases or conditions not previously recognized. These patents provide market exclusivity for the intended use.
• Combination Therapies: Patents may cover formulations combining acetylcysteine with other active pharmaceutical ingredients.
• Manufacturing Processes: Novel or improved manufacturing processes for acetylcysteine API can be patented.

What is the Financial Outlook and Investment Potential for Acetylcysteine?

The financial outlook for acetylcysteine is stable, driven by its essential role in established medical treatments.

• Revenue Streams: Revenue is primarily generated from the sale of both branded and generic oral, intravenous, and inhalation formulations. The demand for NAC as an antidote ensures a consistent, albeit volume-driven, revenue stream.
• Profit Margins: Profit margins on generic acetylcysteine are generally lower compared to patented drugs due to intense competition. However, manufacturers of specialized formulations or those with strong distribution networks can achieve higher margins.
• Investment Considerations: Investment in the acetylcysteine market is likely to yield steady, albeit moderate, returns. Companies focusing on expanding manufacturing capacity for essential generic APIs, developing novel formulations with improved patient outcomes, or successfully navigating regulatory pathways for new indications may present attractive investment opportunities. Research into its potential in areas like neuroprotection or psychiatric disorders warrants monitoring for potential upside.

What are the Key Regional Market Dynamics for Acetylcysteine?

Key regional market dynamics for acetylcysteine include:

• North America: The largest market, driven by high healthcare expenditure, established protocols for acetaminophen overdose management, and a strong demand for respiratory therapies.
• Europe: A significant market with a strong emphasis on respiratory health and the availability of various acetylcysteine formulations. Regulatory harmonization within the EU influences market access.
• Asia-Pacific: The fastest-growing market, fueled by increasing healthcare awareness, rising disposable incomes, a growing patient base for respiratory diseases, and a large generic drug manufacturing sector.
• Latin America and Middle East & Africa: These regions present growth opportunities due to improving healthcare infrastructure and increasing access to essential medicines, including acetylcysteine.

Key Takeaways

• Acetylcysteine's market is anchored by its critical role in mucolytic therapy and acetaminophen overdose reversal.
• The market is projected for steady growth at a CAGR of 4.5% through 2030, propelled by increasing respiratory illness prevalence and overdose incidents.
• Intense generic competition and the expiry of core patents cap pricing power and profit margins for many manufacturers.
• Future growth opportunities lie in novel formulations, expanded therapeutic indications backed by robust clinical research, and penetration into emerging markets.
• Intellectual property is now focused on specific delivery methods, new uses, and manufacturing process improvements rather than the molecule itself.

Frequently Asked Questions

1. Are there any new patented formulations of acetylcysteine that offer significant advantages over existing generics? While numerous patents exist for novel formulations, significant clinical advantages that displace established generic options have been limited. Research is ongoing for specialized delivery systems or combination products, but broad market disruption from new formulations remains a developing area.

2. What is the primary risk associated with investing in a generic acetylcysteine manufacturer? The primary risk is intense price competition and the potential for margin erosion due to oversupply or aggressive pricing by competitors. Dependency on a single product without diversification also poses a risk.

3. How significant is the potential for acetylcysteine in treating psychiatric disorders? Research into NAC's role in psychiatric disorders, including OCD and addiction, is promising but largely in early to mid-stage clinical trials. Regulatory approval for these indications is not guaranteed and would require substantial evidence of efficacy and safety.

4. What impact do fluctuating raw material costs have on acetylcysteine production? Fluctuations in the cost of precursor chemicals for acetylcysteine synthesis can impact production costs. However, for high-volume generic production, manufacturers often secure long-term supply contracts to mitigate this risk.

5. Does the regulatory status of acetylcysteine vary significantly between major markets like the US and Europe? While the core therapeutic indications are generally recognized across major markets, specific approved dosages, formulations, and labeling may differ due to distinct regulatory review processes and requirements by agencies like the FDA and EMA.

Citations

[1] Malloy, J. P., & DeKoven, M. K. (2023). Acetylcysteine. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK563214/

[2] Varghese, J., & Ramakrishnan, G. (2023). Acetaminophen Toxicity. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK557594/

[3] World Health Organization. (2023, May 3). Chronic obstructive pulmonary disease (COPD). WHO. Retrieved from https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

[4] National Institute of Diabetes and Digestive and Kidney Diseases. (2023, July 28). Liver Failure. NIDDK. Retrieved from https://www.niddk.nih.gov/health-information/liver-disease/liver-failure